A recent study found that patients using compounded GLP-1s had a 2.35 times higher risk of hospitalization compared to those on approved versions
Dual Agonists Under Investigation Tirzepatide (Mounjaro) was approved by the FDA on May 13, 2022 for the treatment of type 2 diabetes in adults, making it the first and only GIP/GLP-1 receptor agonist
The likely mechanism is that GLP-1 receptor agonists slow gastric emptying and reduce peristalsis the rhythmic muscular contractions that move stool through the colon
In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s
for their writing assistance and editorial inputs
Neurological Benefits GLP-1 receptors are found in multiple regions of the brain, including the hypothalamus and hippocampus